Northern Trust Portfolio holdings
Northern Trust Corporation, founded in 1889 and headquartered in Chicago, Illinois, is a prominent financial services firm specializing in wealth management, asset management, and asset servicing for high-net-worth individuals, families, and institutions. Known for its conservative and client-focused approach, it manages hundreds of billions in assets, offering trust and custody services, investment solutions, and banking products tailored to affluent clients and organizations like foundations and endowments. The company has built a reputation for reliability and discretion, serving as a custodian for a significant portion of global institutional assets while maintaining a strong presence in private banking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VF Corp
VFC
|
+$939M |
| 2 |
FlexShares Global Upstream Natural Resources Index Fund
GUNR
|
+$517M |
| 3 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$233M |
| 4 |
NXP Semiconductors
NXPI
|
+$195M |
| 5 |
Sherwin-Williams
SHW
|
+$192M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$787M |
| 2 |
Microsoft
MSFT
|
+$337M |
| 3 |
Pinduoduo
PDD
|
+$215M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$212M |
| 5 |
Carnival Corporation Ltd
CCL
|
+$210M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.51% |
| 2 | Financials | 12.87% |
| 3 | Healthcare | 12.23% |
| 4 | Consumer Discretionary | 12.03% |
| 5 | Communication Services | 9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
CRISPR Therapeutics
CRSP
$4.88B
| $7.29M | ﹤0.01% |
59,875
+11,962
| +25% | +$1.81M |
|
2502
Nkarta
NKTX
$154M
| $7.29M | ﹤0.01% |
221,640
+9,461
| +4% | +$452K |
|
|
TARO
2503
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $7.28M | ﹤0.01% |
98,756
-99,783
| -50% | -$7.58M |
|
|
TCRR
2504
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $7.27M | ﹤0.01% |
329,425
-6,965
| -2% | -$190K |
|
|
ALBO
2505
DELISTED
Albireo Pharma Inc
ALBO
| $7.27M | ﹤0.01% |
206,367
-19,972
| -9% | -$737K |
|
|
ATRS
2506
DELISTED
Antares Pharma, Inc.
ATRS
| $7.26M | ﹤0.01% |
1,767,291
-114,910
| -6% | -$498K |
|
2507
Vanguard Morningstar Large-Cap ETF
VV
$53.2B
| $7.26M | ﹤0.01% |
39,182
-13
| -0% | -$2.36K |
|
2508
Par Pacific Holdings
PARR
$4.16B
| $7.26M | ﹤0.01% |
514,038
-71,817
| -12% | -$1.12M |
|
2509
Stoke Therapeutics
STOK
$1.84B
| $7.25M | ﹤0.01% |
186,660
-13,310
| -7% | -$758K |
|
2510
Nurix Therapeutics
NRIX
$2.41B
| $7.23M | ﹤0.01% |
232,677
+94,865
| +69% | +$3.59M |
|
2511
Tenaris
TS
$28.9B
| $7.22M | ﹤0.01% |
318,434
-16,031
| -5% | -$306K |
|
2512
Insteel Industries
IIIN
$602M
| $7.22M | ﹤0.01% |
233,999
-14,749
| -6% | -$440K |
|
2513
Immunovant
IMVT
$7.91B
| $7.21M | ﹤0.01% |
449,651
-17,187
| -4% | -$453K |
|
|
SRG
2514
Seritage Growth Properties
SRG
$137M
| $7.17M | ﹤0.01% |
390,921
-13,461
| -3% | -$249K |
|
2515
Annexon
ANNX
$860M
| $7.17M | ﹤0.01% |
257,360
+79,339
| +45% | +$2.18M |
|
2516
BioXcel Therapeutics
BTAI
$26.2M
| $7.17M | ﹤0.01% |
10,375
-1,342
| -11% | -$1.08M |
|
2517
PDF Solutions
PDFS
$2.01B
| $7.15M | ﹤0.01% |
402,225
-33,548
| -8% | -$665K |
|
|
FRTA
2518
DELISTED
Forterra, Inc
FRTA
| $7.13M | ﹤0.01% |
306,793
-17,593
| -5% | -$379K |
|
2519
Liberty Media Series A
FWONA
$22.4B
| $7.13M | ﹤0.01% |
194,712
-2,605
| -1% | -$97.2K |
|
2520
Alpha and Omega Semiconductor
AOSL
$942M
| $7.12M | ﹤0.01% |
217,591
-23,642
| -10% | -$776K |
|
2521
Hercules Capital
HTGC
$3.15B
| $7.1M | ﹤0.01% |
442,944
+21,393
| +5% | +$332K |
|
2522
Ducommun
DCO
$2.76B
| $7.08M | ﹤0.01% |
117,962
-12,259
| -9% | -$685K |
|
2523
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$22.9B
| $7.05M | ﹤0.01% |
12,901,211
+262,274
| +2% | +$14.4M |
|
|
CNSL
2524
DELISTED
Consolidated Communications Holdings, Inc.
CNSL
| $7.05M | ﹤0.01% |
978,936
-172,139
| -15% | -$1.02M |
|
2525
The RMR Group
RMR
$322M
| $7.04M | ﹤0.01% |
172,595
-7,251
| -4% | -$286K |
|
Similar funds
Northern Trust's Q1 2021 Portfolio in Review
As of Q1 2021, Northern Trust held 4,560 positions worth $538B, up 4.7% from $513B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Northern Trust's Q1 2021 filing shows 186 new, 1,468 increased, 2,748 reduced and 86 closed positions. Its largest new stake was Cognyte Software: 659,566 shares worth $18.3M. The largest sale was Apple, an estimated $787M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Financials and Healthcare.
- Northern Trust's largest Q1 2021 buy was Cognyte Software: 659,566 shares worth $18.3M.
- Northern Trust added most to VF Corp in Q1 2021, an estimated $939M increase.
- Northern Trust's biggest Q1 2021 reduction was Apple, cutting an estimated $787M.
- Northern Trust fully exited Tiffany & Co. in Q1 2021, selling an estimated $147M.
- Northern Trust's ten largest holdings make up 20% of its $538B portfolio in Q1 2021.
- Northern Trust opened 186 new positions and closed 86 in Q1 2021.
- Northern Trust's portfolio value rose 4.7% quarter-over-quarter to $538B.
Based on Northern Trust's 13F filing for Q1 2021, filed 12 May 2021.